High-frequency irreversible electroporation synergizes with PD-1/PD-L1 inhibitor BMS-1 and TLR7/8 agonist R848 to potentiate liver cancer antitumor immunity

Figure 5 High-frequency irreversible electroporation combined with BMS-1 and R848 reprograms the tumor immune microenvironment in hepatoma 22 subcutaneous tumors. A-E: Representative flow cytometry dot plots of intratumoral immune cell subsets post-treatment across all groups: CD3+ CD4+ T cells, CD3+ CD8+ T cells, CD4+ CD25+ FOXP3+ Tregs, CD11c+ CD80+ CD86+ dendritic cells, F4/80+ CD11b+ CD86+ M1 macrophages, and F4/80+ CD11b+ CD206+ M2 macrophages; F-K: Quantitative analysis of the proportions of the above-listed intratumoral immune cell subsets in each group post-treatment (n = 5); L: Quantitative analysis of the intratumoral M1/M2 macrophage ratio across groups post-treatment (n = 5). ^aP < 0.05, ^cP < 0.001, and ^dP < 0.0001. H-FIRE: High-frequency irreversible electroporation.